Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline

Approximately 1.4 million women living with HIV become pregnant every year. Most women use antiretroviral therapy, to reduce the risk of vertical transmission or for personal health reasons. Using the GRADE framework according to the BMJ Rapid Recommendation process, we make recommendations for opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Siemieniuk, Reed A C, Lytvyn, Lyubov, Mah Ming, Jinell, Mullen, Rhonda Marama, Anam, Florence, Otieno, Teresia, Guyatt, Gordon H, Taylor, Graham P, Beltrán-Arroyave, Claudia, Okwen, Patrick Mbah, Nduati, Ruth, Kinuthia, John, Luma, Henry Namme, Kirpalani, Haresh, Merglen, Arnaud, Lesi, Olufunmilayo A, Vandvik, Per Olav, Agoritsas, Thomas, Bewley, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2017
Materias:
Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590100/
https://www.ncbi.nlm.nih.gov/pubmed/28893728
http://dx.doi.org/10.1136/bmj.j3961
Descripción
Sumario:Approximately 1.4 million women living with HIV become pregnant every year. Most women use antiretroviral therapy, to reduce the risk of vertical transmission or for personal health reasons. Using the GRADE framework according to the BMJ Rapid Recommendation process, we make recommendations for optimal choice of combination antiretroviral regimen considering patient values and preferences, the balance of desirable and undesirable outcomes, their uncertainty, and practical issues. We suggest a zidovudine and lamivudine-based regimen over one that includes tenofovir or emtricitabine (weak recommendation). We recommend alternatives over the combination of tenofovir, emtricitabine, and lopinavir/ritonavir (strong recommendation).

Ejemplares similares